Their study explores the metabolic impact of specific mutations within cancer cells, resulting in breast cancer subtypes such as Luminal 1, Luminal 2, HER2+, and triple negative, which can result in altered VOC profiles. This evidence concerns the gene ERBB2 and breast carcinoma.